Methotrexate

Generic Name: Methotrexate

Brand Names: Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₅

CAS Number: 59-05-2

Unique Ingredient Identifier: YL5FZ2Y5U1

Background: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication: Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis

Associated Therapies: Medically induced abortion

Clinical Trials

a Retrospective Study on the Systemic Treatment of LPP and FFA

Completed

Conditions: Cicatricial Alopecia
Lichen Planopilaris
Lichen Plano-Pilaris
Frontal Fibrosing Alopecia
Hair Diseases
Scarring Alopecia
Hair Loss/Baldness

Interventions: Drug: Hydroxychloroquine
Drug: Methotrexate
Drug: Cyclosporine A
Drug: Retinoids

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 315

Registration Number: NCT06512766

Locations: 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial

Recruiting

Conditions: Cicatricial Alopecia
Lichen Planopilaris

Interventions: Drug: Hydroxychloroquine
Drug: Methotrexate

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 56

Registration Number: NCT06512753

Locations: 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy

Not Applicable

Completed

Conditions: Ectopic Pregnancy

Interventions: Drug: Letrozole
Drug: Methotrexate

First Posted Date: 2024-07-16

Last Posted Date: 2024-07-16

Lead Sponsor: Yuzuncu Yıl University

Target Recruit Count: 60

Registration Number: NCT06504082

Locations: 🇹🇷
Yuzuncu Yil University, Van, Tuşba, Turkey

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Phase 4

Recruiting

Conditions: Takayasu Arteritis

Interventions: Drug: Prednisone
Drug: Methotrexate
Drug: Tocilizumab
Drug: Tofacitinib
Drug: Adalimumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-10-17

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 124

Registration Number: NCT06498089

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Phase 1

Recruiting

Conditions: Primary Central Nervous System Lymphoma
Lymphoma

Interventions: Drug: Pembrolizumab
Drug: Methotrexate
Drug: Temozolomide
Drug: Rituximab

First Posted Date: 2024-06-26

Last Posted Date: 2024-11-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT06475235

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States